MedPath

Football Fitness After Breast Cancer

Not Applicable
Completed
Conditions
Breast Neoplasm Female
Interventions
Behavioral: Football fitness
Registration Number
NCT03284567
Lead Sponsor
University of Copenhagen
Brief Summary

Late effects of breast cancer treatment are widely reported including deteriorating fitness, fatigue, loss of muscle and bone mass, and increased body fat percentage. Exercise interventions may ameliorate a number of these effects including fatigue, fitness and improve quality of life. However only limited knowledge exists on the potential of novel interventions and settings, such as sports outside the hospital setting, to improve late effects of breast cancer treatment. The 'Football Fitness After Breast Cancer' (FF ABC) study is a randomized trial comparing the effects of a football training intervention with standard treatment approaches on fitness, bone mineralization, body composition, muscle strength, blood pressure, and patient-reported outcomes in women treated for breast cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
69
Inclusion Criteria
  • Women surgically managed for breast cancer, local and regional advanced breast cancer.
  • Completion of adjuvant chemotherapy and radiation therapy.
  • Legally competent persons with ability to read and understand Danish.
  • Signed informed consent.
  • Performance level 0-1 (WHO).
Exclusion Criteria
  • WHO performance level > 1.
  • Osteoporosis (T-score < -2.5).
  • Known metastatic breast cancer (stage IV).
  • Women in DBCG-group I (age => 60 years, tumor =< 10 mm, invasive ductal carcinoma grade I, invasive lobular carcinoma grade I / II, estrogen receptor positive and HER2 normal).
  • Cardiovascular or pulmonary disorders (e.g., arrhythmias, ischemic heart disease, unregulated high blood pressure, chronic obstructive lung disease).
  • Ongoing anticoagulant therapy (vitamin K antagonists; Marevan, Marcoumar and low molecular weight heparins; Innohep, Clexane, Fragmin) for pulmonary embolism or deep venous thrombosis (DVT) due to increased bleeding risk of falls and clashes with other players during exercise.
  • Current or scheduled chemotherapy and radiation therapy in the intervention period (12 months).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Football fitnessFootball fitnessParticipants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games. Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury.
Primary Outcome Measures
NameTimeMethod
Mean change in fitness level (maximal oxygen uptake) from baseline to month 6 and month 12.6 months and 12 months.

Incremental test to exhaustion on a cycle ergometer.

Secondary Outcome Measures
NameTimeMethod
Mean change in blood pressure from baseline to month 6 and month 12.6 month and 12 month.

Blood pressure will be measured with a digital sphygmomanometer.

Mean change in cholesterol from baseline to month 6 and month 12.6 month and 12 month.

Blood samples will be analyzed at baseline, 6 and 12 month for total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and glycosylated hemoglobin, respectively, by automated analyzers (Cobas Fara, Roche, Neuilly sur Seine, France) using enzymatic kits (Roche Diagnostics, Mannheim, Germany, and Tosoh G7, Tosoh Europe, Tessenderlo, Belgium).

Mean change in whole-body weight from baseline to month 6 and month 12.6 month and 12 month.

Body weight was measured with a digital platform scale.

Mean change in muscle strength from baseline to month 6 and month 12.6 month and 12 month.

Dynamic concentric muscle strength for the knee extensors (1RM).

Mean change in balance from baseline to month 6 and month 12.6 month and 12 month.

Single-leg flamingo balance test.

Mean change in markers of bone mineral metabolism from baseline to month 6 and month 12.6 month and 12 month.

Procollagen type I C propeptide, osteocalcin and C-terminal telopeptide will be analyzed by a chemiluminescence method using a fully automated immunoassay system (iSYS, Immunodiagnostic Systems Ltd., Boldon, England.

Self-reported physical activity from baseline to month 6 and month 12.6 month and 12 month.

Assessed by the International Physical Activity Questionnaire (IPAQ).

Self-reported diagnosis-specific symptoms and side-effects from baseline to month 6 and month 12.6 month and 12 month.

Assessed by the supplement EORTC QLQ-BR23.

Self-reported health-related quality of life outcomes from baseline to month 6 and month 12.6 month and 12 month.

Assessed by the 15 subscales of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).

Mean change in whole-body fat mass from baseline to month 6 and month 12.6 months and 12 months.

Assessed by dual energy x-ray absorptiometry.

Mean change in whole-body muscle mass from baseline to month 6 and month 12.6 month and 12 month.

Assessed by dual energy x-ray absorptiometry.

Mean change in bone mineral density (BMD) of the spine (L2-L4), Total hip and Femoral Neck.6 month and 12 month.

Assessed by dual energy x-ray absorptiometry.

Mean change in total body and leg bone mineral content (BMC).6 month and 12 month.

Assessed by dual energy x-ray absorptiometry.

Self-reported health related quality of life from baseline to month 6 and month 12.6 month and 12 month.

Assessed by The Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36)

Self-reported functional level in upper extremities from baseline to month 6 and month 12.6 month and 12 month.

Assessed by disabilities of the arm, shoulder and hand (DASH).

Trial Locations

Locations (1)

University Hospital of Copenhagen, Rigshospitalet

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath